Researchers devise safer way to dose life-saving heart drug

December 15, 2006

Researchers at the University of Illinois at Chicago have taken the dangerous guesswork out of dosing a lifesaving medication for congestive heart failure.

A new formula developed in the UIC College of Pharmacy will help physicians prescribe the proper amount of the powerful heart drug digoxin. The medication helps an injured or weakened heart to work efficiently, strengthening the force of the heart muscle's contractions and helping to restore a normal, steady heart rhythm.

Digoxin can be difficult to dose, and there is a small cushion between a beneficial and a deadly level of the drug, said Jerry Bauman, interim dean of the UIC College of Pharmacy. Bauman was the lead investigator of a study that was recently published in the Archives of Internal Medicine.

"The therapeutic range for digoxin in heart failure has recently changed to become lower and narrower, and the new range is associated with improved mortality," Bauman said. "However, dosing methods have not been modified to reflect this change. In the study, we sought to develop a new method to determine the initial dose of digoxin in patients with heart failure."

Medical records of adult patients who had a steady state of digoxin concentration in their bloodstream were reviewed for six months. An equation was derived using the patients' blood digoxin level, digoxin dose, kidney function, and ideal body weight.

The new formula was then compared to two older methods frequently used to estimate the initial dose of digoxin, and it was found to be superior. Using the new method, investigators constructed a simple nomogram to help clinicians quickly choose the right dose.

"Because the new therapeutic window of digoxin is associated with improved outcomes, more intensive dosage refinement should be considered," Bauman said. "To this end, we offer new dosing recommendations and a nomogram for determining the initial dose of digoxin in patients with heart failure.

"This is a new way to dose an old drug."
-end-
Bauman was assisted in the study by Robert DiDomenico, clinical associate professor of pharmacy practice; Marlos Viana, associate professor of biostatistics in the department of ophthalmology and visual sciences; and Melissa Fitch, a recent graduate of UIC's pharmacy school.

For more information about UIC, visit www.uic.edu.

University of Illinois at Chicago

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.